Enhanced opportunities for commercialization of Prostatype® available to more laboratories
In collaboration with Karolinska Institutet in Stockholm, Prostatype Genomics has carried out an extensive validation process with the aim of significantly increasing the commercial and technical availability of Prostatype®, the genetic test that measures the aggressiveness of an individual patient's prostate cancer. By validating laboratory kits from additional suppliers as well as several instruments for RNA amplification, many more laboratories can now perform the test as the results from the validations turned out positive.Prostatype Genomics CEO Fredrik Persson comments: "The fact that